Incyte Corp

  • Is This Myelofibrosis Drug a Blockbuster?

    By Kanak Kanti - August 15, 2013 | Tickers: GILD, INCY, SNY

    Bone marrow cancer, also known as Myelofibrosis (MF), is a rare form of cancer that affects both men and women. About 1.5 out of 100,000 people suffer from MF in the U.S. annually, but treatment options are limited. Incyte (NASDAQ: INCY) has developed a small molecule named Jakafi which was approved as first line therapy against MF. Given that this is the only available drug for MF more »

  • A Closer Look at Three Companies Focusing on Myelofibrosis Treatments

    By Leo Sun - August 15, 2013 | Tickers: GERN, INCY, NVS

    Myelofibrosis, a type of chronic leukemia, has been gaining attention among biotech investors recently due to the scarcity of proper treatments. There is currently only one approved treatment on the market, co-developed by Incyte Corporation (NASDAQ: INCY) and Novartis (NYSE: NVS), and an experimental one from Geron Corporation (NASDAQ: GERN). Let’s take a closer look at what myelofibrosis is and the potential future sales of its sparse treatments.

    What more »

  • Is It Time To Invest In Mid & Small Cap Pharmaceuticals?

    By Victor Selva - May 30, 2013 | Tickers: ALXN, CELG, INCY

    Having heard about and invested enough in large-cap pharma, I believe it is time to consider funding smaller firms in the sector. Below you will find three interesting mid and small-cap pharmaceutical companies, Celgene (NASDAQ: CELG), Alexion (NASDAQ: ALXN) and Incyte Genomics (NASDAQ: INCY), with solid growth outlooks. Take a look at them, they might be worthy investments.

    Celgene: A stock with promising future

    A couple weeks ago, Celgene more »

  • Mega-Hedge Fund Focusing on the Life Sciences

    By Meena Krishnamsetty - April 18, 2013 | Tickers: GHDX, INCY, PCYC, SGEN, GEVA

    The $3+ billion Baker Brothers Advisors equity portfolio, managed by brothers Julian and Felix Baker, focuses almost exclusively on life science companies with a small to medium sized market capitalization.

    Why should you watch hedge funds?

    Insider Monkey looks at 450 of the world’s most elite hedge fund managers and our research has shown that over time their picks routinely outperform. Let’s look at the top five picks more »

  • Mega-Hedge Fund Focusing on The Life Sciences

    By Meena Krishnamsetty - April 16, 2013 | Tickers: GHDX, INCY, PCYC, SGEN, GEVA

    The $3+ billion Baker Brothers Advisors equity portfolio, managed by brothers Julian and Felix Baker, focuses almost exclusively on life science companies with a small to medium sized market capitalization.

    Why should you watch hedge funds?

    Insider Monkey looks at 450 of the world’s most elite hedge fund managers and our research has shown that over time, their picks routinely outperform. For more than a decade in our back more »

  • 2 Value BioPharmacetuicals for Your Portfolio

    By Mohsin Saeed - February 26, 2013 | Tickers: ALXN, GILD, INCY

    In my recent articles, I have highlighted that investor’s love for the biopharmaceutical industry has ensured huge returns for some stocks. While this attention is good for the industry and investors have made a lot of money, it becomes pretty hard to find good solid value investments. Therefore I have tried to find a couple of good bargains which have still gone unnoticed and offer exciting opportunity for prospective more »

  • Heroic, But Profitable For Investors?

    By Bill Edson - January 18, 2013 | Tickers: ECYT, IMGN, INCY, NVS, SNY

    Editor's Note: The original article had the market capitalization incorrect for Senesco Technologies and Lorus Therapeutics. This version has been corrected and Motley Fool apologizes for the error.

    Companies like Incyte (NASDAQ: INCY)Immunogen (NASDAQ: IMGN), Endocyte (NASDAQ: ECYT) and Senesco Technologies are putting their research efforts towards the eradication and control of cancers. Though their efforts are often ingenious and heroic, that does not necessarily make them recommendable more »

  • Why This Pharma is Set for a Great 2013

    By Lee Samaha - January 15, 2013 | Tickers: BMY, INCY, NVO, REGN, SNY

    Last year was a pretty good one for stockholders in Sanofi (NYSE: SNY), and the indications are that this year could be the same. It has been a difficult few years for the pharmaceutical industry and I’m sure that in years to come undergraduate management course books will be written on how the companies in the industry dealt with the challenges in different ways. Big pharma has faced patent more »

  • Rheumatoid Arthritis Review – Focus Eli Lilly

    By Shas Dey - December 27, 2012 | Tickers: LLY, INCY, PFE

    Eli Lilly (NYSE: LLY) has been involved in the development of an oral pill for treating Rheumatoid arthritis (RA), an autoimmune disorder characterized by inflammation of joints and surrounding tissue. Today we look at the mixed reports regarding developments on this front and the likely impact on the company’s future prospects.

    Rheumatoid Arthritis: Current Treatment Regime

    Rheumatoid arthritis is marked by abnormal immune mechanisms resulting in inflammation and swelling more »

  • Repeat After Me: My Genes are Patentable and That's Alright

    By Maxxwell A.R. Chatsko - September 12, 2012 | Tickers: BMY, INCY, MYGN, PFE

    The recent Association for Molecular Pathology v. Myriad Genetics patent dispute involving two genes for breast and ovarian cancer, BRCA 1 and BRCA 2, has been widely followed by the media over the last several years. According to some the case highlights a potentially devastating future where humans have no control over their very own genetic code. Even worse, they say, patenting sequences of human DNA limits academic research and more »

  • What Chance do these Blockbusters Really Have of Working?

    By Lee Samaha - April 26, 2012 | Tickers: GILD, INCY, PFE, VRTX, YMI.DL

    If you share my penchant for investing in biotech and pharma, then you will have, no doubt, come across the standard analyst practice of evaluating the NPV of a pipeline. This is critical but, how is it done? Moreover, does the potential blockbuster in your pharma co's pipeline really have as strong a chance of succeeding as you think it does?

    The usual method is to evaluate the pipeline more »

  • Pfizer and its Competition in 2012

    By Lee Samaha - April 12, 2012 | Tickers: LLY, INCY, PFE, VRTX

    Everybody knows that the major pharmaceuticals companies have faced myriad challenges over the last few years. The industry has had to deal with patent cliffs, fears over reimbursement adjustments, the FDA becoming more stringent over approvals, the increasing cost of research and development (R & D) and many other issues.

    The patent cliff issue is immediately noticeable in the slowing revenue growth rates in this period and, this year in particular more »

  • Are Recent Developments in These Stocks Reason Enough To Buy?

    By Brian Gorban - January 24, 2012 | Tickers: BH, CBRL, INCY

    One of my favorite screening tools is to find stocks with notable insider buying. The reasoning is simple as insiders sell for many reasons (diversify one’s assets, pay for the new house, expensive trip with the family, unfortunate divorce settlement costs, etc.), but they buy only for one reason: to make more money. Therefore, these two stocks caught my eye with their recent heavy insider buying.

    Biotechnology firm Incyte more »

  • 3 Pharmaceutical Buyout Targets to Consider in 2012

    By Michael French - January 23, 2012 | Tickers: ANTH, AZN, LLY, INCY, THRX

    Pharmaceutical companies that enjoy monopoly pricing from patented drugs will one day face generic competition and lower profit margins. In 2012 alone, drugs accounting for $63 billion in revenues are expected to lose patent protection, of which $33 billion in sales is forecast to be lost to generic competition and lower prices, according to EvaluatePharma.com.

    Giant pharmaceutical companies have several ways to cope with this foreseeable loss of revenues more »

  • Insiders Are Buying, Should We?

    By Brian Gorban - January 18, 2012 | Tickers: INCY, SHLD

    One of my favorite screening tools is to find stocks with notable insider buying. The reasoning is simple as insiders sell for many reasons (diversify one’s assets, pay for the new house, expensive trip with the family, unfortunate divorce settlement costs, etc.), but they buy only for one reason: to make more money. Therefore, these two stocks caught my eye with their recent heavy insider buying.

    Biotechnology firm Incyte more »

  • J.P. Morgan Healthcare Conference Schedule: Day One

    By Brandy Betz - January 8, 2012 | Tickers: ARAY, ACOR, A, ALGN, AMRN, AMGN, AMLN, ARTC, BIIB, BMRN, BRKR, CFN, CTRX, CELG, CNC, COV, DNDN, XRAY, EW, ENDP, EPOC, ESRX, GHDX, GILD, HLS, HTWR, HMSY, HGSI, IDXX, IPXL, INCY, IRWD, MCK, MRX, MDT, MR, MOH, MYL, NVS, ONXX, PRX, PRGO, QSII, REGN, RMD, RIGL, SGEN, ST, SIAL, THC, MDCO, THOR, VRTX, VVUS, WAT, WMGI, ZLTQ

    The 30th Annual J.P. Morgan Healthcare Conference kicks off with a full day of presentations from companies that range from global pharmaceutical leaders to small cap novel pharmaceutical developers and health technology manufacturers. The majority of the presentations will be available through live webcasts with archived replay offered later in the day.

    I will be following (and covering) the novel therapeutic companies that have caught my eye. VIVUS (NASDAQ: VVUSmore »)